mizoribine

Mizoribine is an imidazole nucleoside immunosuppressive drug originally isolated from the fungus Penicillium brefeldianum (also reported as Eupenicillium brefeldianum) in Japan in 1971[2][4]. It is used primarily to prevent organ rejection in renal transplantation and to treat autoimmune diseases such as lupus nephritis, rheumatoid arthritis, nephrotic syndrome, and IgA nephropathy[3][4][6]. Mizoribine acts by selective inhibition of inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase, thereby blocking the de novo synthesis of guanine nucleotides. This results in suppression of DNA synthesis during the S phase of cell division, particularly affecting T and B lymphocyte proliferation[2][4][6]. Compared to azathioprine, another immunosuppressant with a similar indication profile, mizoribine has lower toxicity. It is typically administered orally.

Brand names

Bredinin

Other names

mizoribinamizoribinumbredinineMZR